Insys Therapeutics (INSY) reached an agreement in principle with the Department of Justice to pay $150 million over the next five years to settle civil and criminal investigations into allegedly illegal marketing of its fentanyl opioid by some of its former employees. The company could pay up to another $75 million, depending upon other undisclosed conditions.

The deal comes amid long-running probes by federal and state authorities into the abuse and misuse of opioid painkillers, and the extent to which they are appropriately prescribed. Insys has figured prominently in this drama, as several former executives and employees have been arrested in connection with allegations of bribing doctors to boost sales of Subsys, which contains fentanyl, a highly addictive opioid.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy